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Background: The MPER region of the HIV-1 envelope glycoprotein gp41 is targeted by broadly neutralizing
antibodies. However, the localization of this epitope in a hydrophobic environment seems to hamper the elicitation
of these antibodies in HIV infected individuals.
We have quantified and characterized anti-MPER antibodies by ELISA and by flow cytometry using a collection of
mini gp41-derived proteins expressed on the surface of 293T cells. Longitudinal plasma samples from 35 HIV-1
infected individuals were assayed for MPER recognition and MPER-dependent neutralizing capacity using HIV-2
viruses engrafted with HIV-1 MPER sequences.
Results: Miniproteins devoid of the cysteine loop of gp41 exposed the MPER on 293T cell membrane. Anti-MPER
antibodies were identified in most individuals and were stable when analyzed in longitudinal samples. The
magnitude of the responses was strongly correlated with the global response to the HIV-1 envelope glycoprotein,
suggesting no specific limitation for anti-MPER antibodies. Peptide mapping showed poor recognition of the
C-terminal MPER moiety and a wide presence of antibodies against the 2F5 epitope. However, antibody titers failed
to correlate with 2F5-blocking activity and, more importantly, with the specific neutralization of HIV-2 chimeric
viruses bearing the HIV-1 MPER sequence; suggesting a strong functional heterogeneity in anti-MPER humoral
responses.
Conclusions: Anti-MPER antibodies can be detected in the vast majority of HIV-1 infected individuals and are
generated in the context of the global anti-Env response. However, the neutralizing capacity is heterogeneous
suggesting that eliciting neutralizing anti-MPER antibodies by immunization might require refinement of
immunogens to skip nonneutralizing responses.Background
The highly conserved Membrane Proximal External
Region (MPER) of the gp41 HIV-1 glycoprotein contains
linear epitopes targeted by the broadly neutralizing anti-
bodies (bnAbs) 2F5, 4E10 and 10E8; all isolated from
HIV-1 infected subjects [1-4]. The ability of the human
immune system to mount a neutralizing response against
this region and their protective activity in animal models* Correspondence: jblanco@irsicaixa.es
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article, unless otherwise stated.[5] made the MPER a promising target for vaccine design
aiming to develop a protective neutralizing response
against HIV-1 [6-8]. However, the elicitation of such
neutralizing responses against the MPER is challenging
likely because of its poor immunogenicity due to topo-
logical constraints or to the existence of immunodo-
minant nonneutralizing regions within gp41 [7,9,10].
Furthermore, some of the features presented by both
2F5 and 4E10 antibodies including lipid recognition and
autoreactivity, represent a considerable immunological
barrier when designing immunogens aiming to mimic
anti-MPER responses [11-13]. The development of the
B-cell cloning technology led to the recent isolation of
the monoclonal antibody 10E8 [4], which is among theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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tified to date. Although it was shown initially to lack the
limiting features presented by the previous anti-MPER
bnAbs [4,14], it has been shown that 10E8 does bind
membrane lipids by two hydrophobic residues in the
CDRH3 loop, suggesting that anti-MPER bnAbs could
mediate neutralization by similar mechanisms where the
binding to the viral membrane plays a role [15]. Despite
this controversy, it seems that the presentation of MPER
epitopes in a lipid environment or in a soluble form may
modify its recognition by anti-MPER antibodies [16,17].
The efforts to characterize bnAbs against the MPER
have abridged the full characterization of other anti-
MPER humoral responses, which also include several anti-
bodies with low or null neutralizing capacity [3,18]. The
characterization of these nonneutralizing anti-MPER anti-
bodies may provide further insights in the mechanisms
and molecular determinants of neutralization. For this rea-
son, we aimed to characterize the diverse MPER responses
in HIV-1 infected individuals. To this end, we developed
small gp41-derived proteins that properly exposed the
MPER epitopes recognized by 2F5 and 4E10 BnAbs on
the surface of HEK-293T cells. By using cell lines stably
transfected with these proteins, we characterized plasma
samples from untreated HIV-1 infected individuals. We
could detect anti-MPER antibodies in most of these in-
dividuals. Furthermore, we found that MPER-specific
responses were elicited in the context of a global re-
sponse against the envelope, which suggest that there is
no specific constraint in the elicitation of anti-MPER
antibodies. Further characterization of the MPER-specific
neutralizing activity showed that anti-MPER responses
were highly heterogeneous in terms of neutralization and
specific epitope recognition.
Results
Generation and characterization of gp41-derived proteins
We designed a series of proteins containing the MPER of
gp41 by generating deletion mutants of gp41 (Figure 1A).
Starting from a complete gp41 sequence devoid of the
cytoplasmic tail (GP41-EC), we sequentially removed
the fusion peptide to generate the GP41-2 L (2 helicoidal
regions and loop) protein, the HR1 and the loop region to
generate the GP41-MIN protein. Finally, we fused the fu-
sion peptide to the MIN protein to limit HR2 flexibility
and to putatively increase the association of the protein to
the membrane (GP41-STAPLE construct, Figure 1A). All
proteins were cloned in pcDNA3.1 expression vectors
fused with a GFP sequence at the C-terminal end and
transiently transfected in 293T cells to assess MPER ex-
posure on the surface of transfected cells. As shown in
Figure 1B, all proteins were similarly expressed as assessed
by the intensity of GFP expression, although the proper
exposure of MPER epitopes on the cell surface differedamong constructs. The binding of two different anti-
MPER antibodies (4E10 and 2F5) to the GP41-EC protein
was hardly detectable, and the removal of the fusion pep-
tide had little effect on cell surface MPER exposure, that
remained only detectable at low level using the 2F5 anti-
body. Conversely, removal of the loop and the HR1 region
greatly increased MPER exposure that become readily de-
tectable by 4E10 and 2F5 in GP41-MIN transfected cells.
Addition of the gp41 fusion peptide at the N-terminal end
failed to increase cell surface expression of MPER, rather
a decrease was observed for the binding of the 4E10 anti-
body (Figure 1B).
We selected GP41-MIN and GP41-STAPLE constructs
to determine the level of anti-MPER antibodies in HIV-1
infected individuals, and generated 293T cell lines stably
expressing these proteins. For comparative purposes, a
293T cell line stably expressing the full-length HIV-1
envelope (gp160 protein, isolate NL4.3) was also selected.
293T cells expressing GP41-MIN and GP41-STAPLE
showed higher level of cell-surface MPER exposure than
cells expressing full-length Env as assessed by 2F5 stain-
ing. The low 2F5 signal in the latter cell line was not due
to low full-length Env expression, since a strong positive
signal was obtained after staining with the 2G12 anti-
gp120 antibody (Figure 1C). Plasma from an HIV-1 in-
fected individual showed reactivity against all cells,
while background levels of antibody binding were de-
tected when plasma from an uninfected individual was
used (Figure 1C).Analysis of anti-gp41 responses in HIV-1 infected
individuals
Stably transfected cell lines characterized in Figure 1C
were used to analyze the binding of 35 plasma samples
obtained from viremic untreated HIV-1 infected indi-
viduals. Recognition of MIN, STAPLE and full-length
Env was assessed by calculation of the ratio of MFI from
each plasma obtained in the different cell lines and the
MFI obtained using a control untransfected 293T cell
line (Figure 2A). Background staining was defined as
MEAN + 2xSD of values obtained using 10 plasma sam-
ples from uninfected individuals and showed that 94%
of samples yield positive signals against GP41-MIN pro-
tein, 85% against GP41-STAPLE and 97% against the full-
length Env. No major differences among HIV-1 infected
individuals were found when samples were classified ac-
cording to VL, only a lower global anti-Env response was
noticed in the group of patient showing VL < 5000 copies/
ml (Figure 2A). The stability of humoral responses was
assessed using longitudinal samples separated at least one
year (Figure 2B) that showed a general conservation of
specific responses; only a significant increase was observed
for anti-gp41-MIN antibodies in the lowest VL group
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Figure 1 Characterization of gp41-derived proteins. Panel A. Different gp41-derived proteins used in this study are depicted. The different
regions of gp41 are depicted in blue (fusion peptide), red (helicoidal region 1, HR1), brown (disulfide loop), green (HR2), yellow (membrane
proximal external region, MPER) and purple (Transmembrane region, TM). The GFP fused to the C-terminal sequence is also depicted in light
green. Panel B. Flow cytometry analysis of MPER exposure on the surface of transfected cells. 293T cells transiently transfected with the constructions
shown in panel A were analyzed for cell surface MPER exposure. Plots of GFP expression and binding of control, 4E10 and 2F5 antibodies are shown.
Panel C. 293T cells stably expressing the MIN (left panels) or STAPLE (middle panels) constructions were selected and the binding profile of different
antibodies was compared with a 293T cell line stably expressing a full-length HIV-1 envelope construct (right panels). Antibodies tested were the
anti-MPER mAb 2F5, the anti-gp120 glycan shield mAb 2G12 and plasma samples from HIV-1 infected or uninfected individuals.
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VL (data not shown).
Furthermore, a strong correlation was observed be-
tween the recognition of GP41-MIN and GP41-STAPLE
when all samples were analyzed (Figure 3) emphasizing
the similarities between both proteins tested. Interestingly,
the amount of antibodies bound to both gp41-derived pro-
teins strongly correlated with the total anti-Env response
(Figure 3), suggesting that anti-gp41 responses are gener-
ated in the context of a potent general anti-Env response.
Mapping anti-gp41 responses
To determine the peptidic regions recognized by plasma
samples and to evaluate the potential differences in rec-
ognition of soluble and membrane bound forms of our
proteins we performed a series of ELISA assays using a
purified full-length MIN protein, the C34, T20, MPER
and OLP#19 peptides covering respectively the 628–661, 638–673, 659–683 and 671–684 residues of gp160
(HXB2 numbering, Figure 4A). All plasma samples from
HIV-1 infected individuals recognized the soluble form
of MIN protein with titers above the cutoff defined by
uninfected individuals (Figure 4B). However, the recog-
nition of the MPER peptide yielded positive titers for
66% of plasma samples (Figure 4B). A similar percent-
age of samples recognized the T20 peptide, which con-
tains the 2F5 core epitope but lacks the 4E10 binding
motif (Figure 4B), while a lower percentage of samples
(55%) yielded positive titers for C34 peptide binding
(Figure 4B) and only 17% of samples recognized the
OLP#19 peptide encompassing the 4E10 epitope. Fur-
thermore, a strong positive correlation was found be-
tween anti-MPER responses and both the recognition of
cell surface expressed MIN protein and anti-T20 titers
(Figure 4C), while a poor correlation was observed be-
tween anti-MPER titers and either anti-C34 antibodies
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Figure 2 Identification of anti-MPER antibodies in HIV-1 infected individuals. Panel A. The presence of antibodies recognizing the MIN,
STAPLE or full-length HIV-1 envelope was tested using the 293T cells stably expressing these proteins. The upper plots show the ratio of mean
fluorescence intensity (MFI) of plasma IgG bound to 293–MIN, 293-STAPLE or 293-ENV (full-length) and control 293 cells. Plasma samples from
HIV-1 infected individuals were classified according to plasma viral load (VL > 50000, 50000 < VL < 5000 and VL < 5000). Plasma samples from
uninfected individuals (HC) were tested as control. Dotted lines show the positivity cutoff calculated as Mean + 2xSD of uninfected plasma samples.
Panel B. The longitudinal evolution of MIN, STAPPLE and full-length HIV-1 envelope recognition by plasma samples from HIV-1 infected individuals is
shown for the different VL groups defined in Panel A. Time points are separated at least one year. All figures show the ratio of MFI between cells stably
expressing MIN (left) STAPLE (middle) or full-length envelope (ENV, right) and 293T control cells. Significant p values are shown.
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Figure 3 Antibodies against Gp41-MIN and Gp41-STAPLE are elicited in the context of a wide anti-Env response. Spearman´s correlation
analysis of the signals obtained between 293-MIN and 293-STAPLE cell lines (left panel) and between both cell lines and 293-ENV cell line (middle
and right panels, respectively). Figures show the correlation coefficient (r) and p values (p).
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http://www.retrovirology.com/content/11/1/44or anti-4E10 epitope antibodies (Figure 4C). Altogether
these data suggest that a robust response against the
2F5 epitope is generated in HIV infected individuals.
Therefore, we assayed the functional binding of plasma
antibodies to MPER in a competition assay using 293T
cells expressing the gp41-MIN protein and labeled 2F5
antibody. As expected, plasma from HIV-1 infected indi-
viduals induced a significant blockade of the 2F5 epitope
compared to background levels induced by control unin-
fected samples (Figure 4D). However, the extent of in-
hibition was not correlated to the titers of anti-MPER
antibodies measured by different methods: direct bind-
ing to MIN or STAPLE proteins or MPER peptide ELISA
(Figure 4D), suggesting heterogeneity in functional bind-
ing to the targeted epitopes.
Neutralization capacity of plasma samples
The potency of neutralization of different HIV-1 isolates
(NL4.3, BaL, AC10 and SVBP16) was evaluated for
plasma samples in TZM-bl cells. A positive correlation
was found between the levels of MIN recognition and
the neutralization titers for all isolates (data not shown).
However, this observation is probably related to the strong
correlation between anti-MIN antibodies and global anti-
Env responses that may mediate neutralization. Therefore
to ascertain the specific neutralizing capacity of anti-
MPER antibodies detected in plasma samples, we tested
plasma samples against a collection of chimeric HIV-2
viruses engrafted with different MPER sequences [19].
IC-50 values were calculated for the wild type (wt) HIV-2,
HIV-2 containing the full MPER sequence (aa 661–684),
the 2F5 epitope (aa 661–670) or the 4E10 epitope (aa
671–684). The increase in IC-50 between the wt and the
different engrafted viruses was assumed to be the specific
contribution of MPER or specific regions to neutralization
(Figure 5A). Using this approach, only a percentage of
plasma samples showed specific neutralization against
the full MPER sequence. Neutralizing activity was
hardly detected when using HIV-2 viruses engrafted
with shorter epitopes of either 2F5 or 4E10 antibodies.A direct comparison of neutralizing plasma with those
lacking neutralization capacity showed an unexpected
similarity in ELISA, or flow cytometry parameters evalu-
ated to quantify MPER recognition (Figure 5B). Indeed,
several plasma samples exhibited high titers of anti-MPER
antibodies in the absence of measurable neutralization
capacity (see samples 15, 5 and 12 in Figure 5B), while
several plasma samples showed an inverse behavior,
with neutralizing capacity in the absence of high anti-
MPER titers (samples 25 or 28). Furthermore, the longi-
tudinal analysis of several plasma samples confirmed a
robust reproducibility in the different parameters mea-
sured, indicating that the very diverse profiles in gp41
humoral responses are stable overtime (see Additional
file 1). In summary, these data suggest that both neu-
tralizing and nonneutralizing responses are generated
against the MPER epitope and that standard or new epi-
tope binding measurements hardly identify neutralizing
activity of polyclonal plasma samples.
Discussion
The MPER of gp41 is an attractive vaccine candidate
that exposes linear peptides as target of broadly neutral-
izing antibodies. However, the particular localization of
the MPER in the HIV-1 envelope glycoprotein trimer
may represent a limiting factor for neutralizing activity.
Indeed, this sequence is partly inserted in the viral or
cellular membrane due to its amphiphilic properties [7],
and is located in the base of the inverted pyramid formed
by the envelope trimer [20]. However, monoclonal anti-
bodies against the MPER have been shown to exert similar
protective effects than anti-gp120 antibodies in non
human primate models [5]. Therefore the elicitation of
neutralizing anti-MPER responses by several candidate
immunogens is still a major issue in HIV vaccine research,
although it has been unsuccessful to date [21-24].
All these failed attempts may be explained by the
requirement of hydrophobic residues in the CDRH3
loop of anti-MPER antibodies to allow them to access
the hydrophobic environment of the targeted sequence
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Figure 4 Mapping anti-gp41 responses. Panel A. Schematic representation of the antigens used for our fine mapping of anti-gp41 responses.
Amino acid sequences of a recombinant full-length MIN protein and peptides C34 (gp41 aa 628–661), T20 (gp41 aa 638–673), OLP#19 (gp41 aa
671–684) and MPER (gp41 aa 659–683) are displayed. Panel B. Specific IgG titers for the recognition of MIN, MPER, T20, OLP#19 and C34 peptides
by plasma samples. Titers are indicated in equivalents of 2F5 in ng/mL for MIN, T-20 and MPER or 4E10 equivalents in ng/ml for OLP#19. For C34
Arbitrary Units (AU) relative to one highly positive plasma sample used as standard are indicated. Panel C. Spearman´s correlation between
standard anti-MPER ELISA assay and specific IgG signal displayed by 293-MIN cell line stained by plasma samples from HIV-1 infected individuals,
anti-T20 ELISA titers, anti-C34 ELISA titers and anti-OLP#19 ELISA titers. Panel D. Plasma samples from HIV-1 infected individuals and healthy
controls (HC) were tested in a competition assay by using the 293-MIN cell line and a fluorescently-labeled 2F5 antibody. The percentage of
blockade of 2F5 binding is shown for both groups of samples. Correlations between 2F5 blockade and specific recognition of 293-MIN, 293-STAPLE
and anti-MPER ELISA titers by plasma samples are shown. 2F5 competition assays and fine gp41-peptide mapping confirms the presence of anti-MPER
antibodies in plasma from HIV-1 infected individuals. In panel B and D, ***denotes p < 0,001. In panels C and D the correlation coefficient (r)
and p values (p) are shown.
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http://www.retrovirology.com/content/11/1/44[21]. This is the case of the different bnAbs isolated
[7,15]. Furthermore, the hydrophobic CDRH3 regions
recognize lipids [7,15] and at least 2F5 and 4E10 bnAbs
are also cross reactive with human proteins, thus suggest-
ing that tolerance may limit anti-MPER responses [25,26].
All these limitations seem to favor the diversion of
humoral immune responses towards other gp41 regions,
in particular the external loop, which has been described
as an immunodominant nonneutralizing region [27].
To evaluate the impact of the latter limitations in the
generation of anti-MPER antibodies, we analyzed the re-
sponses against the MPER elicited by natural infection.
Responses were quantified by using miniproteins devoid
of the immunodominant regions of gp41 but containing
the HR2 sequence adjacent to the MPER. Maintaining
this region was necessary since removal of the HR2 se-
quence reduced the binding of 2F5 to the cell surface
expressed miniproteins (data not shown, Carrillo et al.
in preparation). Unexpectedly, most HIV-1 infected in-
dividuals showed specific recognition of two different
miniproteins displaying the HR2 and the MPER regions
of gp41. In fact, both proteins only differ on the flexibil-
ity of the HR2 sequence, being this region free in the
MIN protein, while conformationally constrained by the
potential interaction of the fusion peptide with the
membrane in the STAPLE protein. Thus, the strong as-
sociation between the recognition of these two proteins
suggested that anti-MPER antibodies were responsible
for binding. This observation was further confirmed by
classical ELISA assays using full length MIN protein,
and C34, T20 and MPER peptides; the latter peptides
share the N-terminal MPER sequence and showed strong
positive correlation in ELISA data. Consistently, a peptide
spanning the C-terminal moiety of MPER, OLP#19,
showed much lower reactivity. These data reinforced
the notion that HIV-1 infected individuals develop anti-
MPER antibodies, mainly against the 2F5 epitope, that
are stable overtime. Furthermore, another relevant ob-
servation is that strong anti-MPER responses occur in
patients with strong anti-Envelope responses, suggest-
ing that no specific requirements are needed for such aresponses, and that the general immunocompetence,
defined by the suboptimal function of CD4 and B cell
compartments [28], may be the main limiting factor in
the elicitation of strong humoral responses in natural
HIV-1 infection. Finally, our analysis also searched for im-
mune correlates of viral control; however, no correlation
of viral load was observed with any measured parameter,
either related to MPER-specific or general anti-Env re-
sponses. This is consistent with previous data showing a
lack of correlation between neutralizing activity and
virological control and progression to AIDS [29,30].
While the wide presence of anti-MPER responses
could be good news for the development of MPER based
immunogens, our data point to a more negative aspect,
the strong functional heterogeneity of the anti-MPER
antibodies detected in HIV-1 infected individuals. We
show that plasma samples show divergent neutralizing
capacity or ability to block 2F5 binding and that both
activities are unrelated to the level of anti-MPER anti-
bodies measured by flow cytometry or ELISA. Several
reasons may explain these paradoxical results. The exist-
ence of nonneutralizing anti-MPER antibodies, that may
compete for the 2F5 binding epitope, has been reported
in mice and rhesus macaques immunized with MPER-
containing proteins [18,31]. These antibodies seem to be
also generated in the context of natural HIV-1 infection
and may provide positive results in flow/ELISA assays
that detect MPER binding, while failing to induce detect-
able neutralization. Consistently, a wide analysis of gp41
responses showed that all monoclonal antibodies elicited
in humans against the cluster II of gp41 lacked neutral-
izing activity [32]. Similarly, llama immunization with
liposomal formulations of gp41 miniproteins is able to
induce neutralizing antibodies despite the absence of
neutralizing activity observed in plasma samples [21],
suggesting that nonneutralizing antibodies may not only
divert neutralizing immune responses but also block the
binding of neutralizing antibodies elicited, as shown for
gp120 C1 antibodies [33]. However, the ability of nonneu-
tralizing antibodies to bind MPER may allow them to
interfere with HIV-1 replication by alternate mechanisms,
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Figure 5 MPER-like neutralization capacity of selected plasma samples shows diverse antibody specificities. Panel A. Example of the
neutralization profile of one plasma sample against a collection of chimeric HIV-2 viruses engrafted with the whole MPER region or the 2F5/4E10
epitopes. Specific neutralization capacity was calculated as the ratio of IC50 between engrafted viruses and wild type HIV-2, corresponding with
the curve shift relative to that for wild type HIV-2. Panel B. Bar graph shows the level of specific MPER-like neutralization, expressed as described
in panel A. Numbers on the top of bars indicate patient code. The table displays the values of the different parameters evaluated in the study for
each tested plasma sample. Color code is indicated in the lower right corner.
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(ADCC) that seems to be a protective factor in the
RV144 study [34] and has been described for neutraliz-
ing anti-MPER antibodies [35]. Our data also provide
evidence for a completely opposite setting, the presence
of neutralizing antibodies that poorly bind peptidic se-
quences (this is the case of samples 25 and 28 in Figure 5B
and Additional file 1). In these cases, flow cytometry ap-
proaches yield higher positivity, suggesting the involve-
ment of lipid membranes in binding to the target epitopes
and therefore a benefit of flow cytometry methods to
detect these antibodies.
Conclusions
Given the great complexity of the immunogenicity of the
MPER, it seems necessary to better understand the natural
humoral response to this region. For instance, further
characterization of new monoclonal antibodies isolated
from HIV-1 infected individuals displaying high titers of
anti-MPER antibodies with neutralizing and nonneutra-
lizing activity will be beneficial for the definition of the
mechanisms and the structural requirements involved
in the elicitation of broadly neutralizing antibodies. In
this regard, the role of nonneutralizing antibodies should
be defined. These data will provide an improved frame-
work for the design of novel MPER-based immunogens
that directs the humoral response towards neutralizing
activities.
Methods
Samples
We selected plasma samples from untreated HIV-1 in-
fected individuals according to the following criteria:
HAART naïve individuals with VL > 50 copies/ml, with at
least two plasma samples available separated by one year.
A total of 35 individuals fulfilled selection criteria and
were classified in three groups according to the VL in the
first time-point analyzed: Group 1: VL > 50000, Group 2:
50000 > VL > 5000 and Group 3: VL < 5000 copies/mL.
Blood from 10 uninfected healthy donors were collected
by venipuncture. Plasma was prepared by blood centrifu-
gation for 10 minutes at 3000 × g.
Construction of Gp41 derivatives
The pHXB2 plasmid containing a full HIV-1 sequence
and the peGFP plasmid containing an eGFP codingsequence were used to amplify gp41 and GFP se-
quences. The primers were designed according to pub-
lished sequences, and were as follows (5´-3´): i) for the
fusion peptide region GP41-EC-f CACCATGGCAGT
GGGAATAGGAGCTATG and FP-r TACCGTCAGCGT
CATTGAGGCTG; ii) for the HR1 region GP41-2 L-f
CACCATGCAGGCCAGACAATTATTGTCTG; iii) for
the HR2 region GP41-MAX-f CACCATGATTTGGAA
TAACATGACCTGG and HR-2 f-2 GCTGACGGTA
ATTTGGAATCACACGACCTGG; iv) for the trans-
membrane region GP41-r GCCACCGCCACCTAGCT
CTATTCACTATAGA and v) for the intracellular re-
gion GP41-MAX-r GCCACCGCCACCTAGCAAAATC
CTTTCCA. The bold text indicates overhang sequences
for directional cloning. The italic text indicates overlap-
ping sequences for the generation of fused proteins. All
amplification reactions were performed using Amplitaq
DNA polymerase (Applied Biosystems) in a 2720 Ther-
mal cycler (Applied Biosystems). For each construct, an
additional plasmid containing the green fluorescent
protein (GFP) coding sequence fused to gp41 in C ter-
minal was constructed. The final PCR products were
cloned into a pcDNA vector using the pcDNA 3.1 Dir-
ectional TOPO® Expression Kit (Invitrogen). The posi-
tive clones were selected in ampicillin plates, recovered,
screened by PCR, sequenced and then tested for func-
tional expression. A previously reported pcDNA3.1
plasmid coding for the NL4.3 envelope gene was used
to express the full-length envelope [36].
Transient and stable expression in 293T cells
Human embryonic kidney HEK-293T cells (ATCC Ac-
cession No. CRL-11268) were cultured in DMEM
medium (Invitrogen) supplemented with 10% fetal calf
serum (Invitrogen). One day before transfection, the
cells were detached using versene (Invitrogen), washed
in supplemented DMEM and split in six well plates at a
density of 400000 cells/well. For transfection, each well
was transfected with 2 μg of one of the plasmids coding
for gp41constructs described herein using the CalPhos
Mammalian Transfection Kit (Clontech). Transient ex-
pression was assayed 24–48 hours after transfection.
Stable expression of gp41 proteins was assayed by flow
cytometry after culturing transfected cells in supple-
mented DMEM containing 1 mg/ml of the selection anti-
biotic G418 (Invitrogen). Transient and stable expressions
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total levels of gp41 proteins in cell extracts. In addition,
molecular weight, western blot analysis, MPER integrity,
antibody recognition and residual fusogenic activity assays
were also performed.
293T cells were stained with the anti-gp41 2F5 or 4E10
monoclonal antibodies (Polymun Scientific) at a concen-
tration of 4 μg/ml for 30 minutes at room temperature.
After washing, bound antibodies were revealed using a
PE-labeled Goat-anti-human IgG (Jackson ImmunoRe-
search) and analyzed in a LSR II flow cytometer (Becton
Dickinson). The level of expression was determined as
the % of positive cells or the Mean Fluorescence Inten-
sity (MFI). Mock transfected HEK-293T cells were used
as negative controls. The ratio of MFI observed for sam-
ples and negative controls was measured as a surrogate
parameter of MPER exposure.
Peptides and proteins
HIV-1 IIIB C34 and T20 peptides were obtained
through the NIH AIDS Reagent Program (Division of
AIDS, NIAID). A 28-mer MPER peptide (EQELLELDK-
WASLWNWFNITNWLWYIKL) was ordered to Ther-
moFisher Scientific. The OLP#19 peptide covering the
C-terminal part of MPER was kindly provided by C.
Brander (IrsiCaixa, Spain). MIN sequence was cloned in
a pET-21d(+) expression vector (Novagen) and produced
by E. coli BL21 DE3 strain (Invitrogen). Inclusion bodies
were prepared from 1 L of bacterial culture and solubilised
using 8 M urea. Highly pure protein was obtained through
niquel-based Immobilized Metal Affinity Chromatography
(GE Healthcare) and gel filtration using a Sephacryl S-100
HR column (GE Healthcare).
Enzyme Linked Immunosorbent Assays
Peptides C34, T20, OLP#19, MPER and recombinant MIN
protein were coated in 96-well Maxisorp Nunc-immuno
plates (Fisher Scientific). After blocking, plates were incu-
bated with 100 ul of previously diluted plasma samples
overnight at 4°C. Plates were then washed and 100 ul of a
Horseradish Peroxidase (HRP)-conjugated F(ab)2 Goat
antihuman IgG (Fc specific) (Jackson Immunoresearch)
were dispensed for one hour at room temperature. Plates
were developed with 100 ul of O-Phenylenediamine dihy-
drochloride (OPD) substrate (Sigma-Aldrich) and stopped
with 100 ul of 4 N H2SO4. Optical density was measured at
492 nm for specific signal and at 620 nm for background.
2F5 competition assay
The 2F5 antibody was labeled with the DyLight 649
Microscale Antibody Labeling Kit (Pierce) and titrated
in 293T cells expressing MIN protein. Competition of
plasma samples with labeled 2F5 was performed by
preincubating 293-MIN cells with 1/10 dilutions ofplasma for 15 minutes at room temperature, and then
with 0.5 ug/ml of 2F5 for 30 min. Cells were washed in
PBS, fixed in FA 1% in PBS and analyzed by flow
cytometry.
Viruses and neutralization assays
HIV-2 chimeras were made in the context of the full-
length p7312A HIV-2 molecular clone (GenBank acces-
sion number L36874). Expression vectors for the wild
type HIV-2 (p7312A) and HIV-2 chimeras containing
the HIV-1 gp41 Membrane Proximal External Region
(p7312A-C1), the 2F5 (p7312A-C3) or 4E10 epitopes
(p7312A-C4), were kindly provided by G.M Shawn (Uni-
versity of Pennsylvania) [19]. Pseudoviruses were gener-
ated by transfection of plasmids in 293T cells. After
24 hours post-transfection, supernatants were harvested,
filtered at 0.45 micron and viral stocks frozen at -80°C.
HIV-1 isolates NL4.3, BaL, AC10 and SVP16 were
generated as pseudoviruses using Env expression plas-
mids and the pSG3 vector as described [37]. Cell-free
virus neutralization by plasma samples was tested by a
standard TZM-bl based assay [38]. Briefly, in a 96-well
culture plate, 100 ul of previously diluted plasma sam-
ples were preincubated with 50 ul of pseudovirus stock,
using 200 TCID50, at 37°C, one hour. Then, 100 ul con-
taining 10,000 TZM-bl luciferase-reporter target cells
per well were added. Plates were cultured at 37°C and
5% CO2 for 48 hours. 2F5, 4E10 and IgGb12 (Polymun
Scientific), and anti-CD4 clone SK3 (BD Biociences) were
used as controls. Plasma samples were inactivated (56°C,
30 minutes) prior to the assay and threefold serial dilu-
tions were tested, from 1/60 to 1/4960. TZM-bl reporter
cells were treated with dextran (Sigma Aldrich) to enhance
infectivity. Luciferase substrate, Britelite Plus (Perkin-
Elmer) was used for the read out.
Statistical analysis
Variables were expressed as the median (interquartile range)
and compared using Mann–Whitney test. Spearman’s cor-
relation coefficient was calculated to assess the association
between variables. Non-linear fit of neutralization data
were calculated using normalized values fitted to an one-
site inhibition curve with fixed Hill slope [39]. All statis-
tical analyses and non-linear fitting were performed using
the GraphPad Prism v5.0 software. Positivity cutoffs for
ELISA and flow cytometry assays were calculated using
the MEAN+ 2xSD of values obtained using HIV-1 sero-
negative individuals. Bonferroni correction has been calcu-
lated for multiple comparisons.
Additional file
Additional file 1: Analysis of stability overtime of different markers
for anti-MPER humoral response.
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